Clinical trials show promise for psychedelic treatments for anxiety and depression

Recent clinical trials have reported positive results for psychedelic-based treatments targeting treatment-resistant depression and generalized anxiety disorder.

Definium Therapeutics, formerly known as MindMed, reported successful Phase 3 trial results for DT120, an oral lysergic acid derivative tablet. In the Voyage trial, DT120 showed a 5.4 point reduction on the HAM-A scale compared to a placebo after 12 weeks. A separate trial, Panorama, involving 245 adults, showed that a 100 microgram dose reduced anxiety by 9.8 points, significantly outperforming the placebo. Most patients were clinically discharged within eight hours of administration.

In a separate development, studies published in JAMA and JAMA Psychiatry indicate that 5-MeO-DMT, a synthetic version of a compound found in the Sonoran Desert toad, may alleviate symptoms in patients with treatment-resistant depression. A study involving 193 adults used an intranasal formulation, BPL-003, developed by AtaiBeckley. The research suggests that a single session can provide relief for several weeks, offering a different mechanism of action than daily antidepressants by interacting with serotonin receptors to reorganize neural network communication.